About Yifan

Home > About Us > About Yifan

        Yifan Pharmaceutical Co., Ltd. is an A-share company listed at Shenzhen Stock Exchange. Abbreviation of the security is Yifan Pharmaceutical while the security code is 002019.
       As one pharmaceutical enterprise focusing on innovation, R&D and manufacturing, Yifan Pharmaceutical has the Yifan Research Institute, a national post-doctoral research station and a enterprise technology center (R&D center) at provincial level. With several high-tech enterprises, Yifan now has more than 100 masters and doctors majored in pharmacy and related fields, owns two advanced biologics innovation R&D platforms with DiKineTM and ITabTM, holds almost 100 international and domestic patent authorization, among which, 35 are international patents.
        Yifan has undertook National “Tenth Five-Year Plan” Key Projects, National High-tech Industrialization Demonstration Projects and National Torch Projects, and has obtained the second prize for State Invention Award and National Prize for Progress in Science and Technology respectively.
        Guided by expertise, specialization and product portfolio in target therapeutic areas as guidance, Yifan has continuously innovating, transformatively upgrading, focusing on macromolecular biologics, high-end chemical drug, special Traditional Chinese Medicine and other key therapeutic areas. Dozens of high-end chemical drugs are under development, and ten of them are at clinical or ANDA application stages, and Yifan holds over 400 approval numbers for marketing of drugs in therapeutic areas of gynecology, pediatrics, dermatology and etc. 40 of these drugs are exclusive to the company, and 20 of which are covered by national health insurance. Several macromolecule biological drugs are in global phase II and III studies. As one Chinese enterprise first having macromolecule innovative drugs for phase II and III clinical testing in America,Yifan will lead Chinese biologics to knock on America’s door.
        Yifan has already formed the manufacturing center of high-end chemical drug and herbal products in Anhui Province, manufacturing center of dermatological and gynecological products in Sichuan Province, manufacturing center of orthopedics drug and therapeutic infusion center in Liaoning Province, R&D center and manufacturing centers of macromolecule biologics in Beijing and Shanghai and API manufacturing center in Zhejiang.
        Pharmaceutical business of Yifan has covered all provinces and cities but Hong Kong SAR, Macau SAR and Taiwan, and the coverage rate of pharmaceutical preparations in second-class hospitals in China exceeding 60%. Meanwhile, as one of the largest manufacturer and supplier of pantothenic acid and Provitamin B5, the sales network of API of Yifan has radiated many countries and regions in Europe, US and etc, and has leading the global market with the market share is 40% -45%.

        Facing the future, Yifan will constantly focus on pharmaceutical and healthcare industry, adhere to the development strategy of “integration, innovation, and globalization”, abide by the core value of “pragmatism, innovation, honesty and diligence”, commit to bring benefits to customers, build development platform for employee, achieve wealth for shareholders, create value for society, and continue to grow as the expert in global pharmaceutical and healthcare industry.